The therapeutic candidate allopregnanolone is safe and well-tolerated in people with early Alzheimer’s disease, according to data from a Phase 1b/2a clinical trial that also investigated the medication’s maximum-tolerated dose. Moreover, MRI scans showed that allopregnanolone — dubbed ALLO by researchers — may protect against brain tissue loss in these patients. “Allopregnanolone was well-tolerated and safe across all doses. Safety, MTD [maximum tolerated dose] and [pharmacokinetic] parameters of ALLO support advancement to a Phase 2…
May 01, 2022May 1, 2022